Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Monoclonal antibodies in the clinic

Nature Biotechnology volume 19, pages 819–822 (2001)Cite this article

Despite initial teething problems, the number of clinically effective monoclonal antibodies is growing.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Number of mAbs entering clinical studies by year.

© Mark Sokoloff

References

  1. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).

    Article  CAS  Google Scholar 

  2. Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311 (1986).

    Article  CAS  Google Scholar 

  3. Morrison, S.L. et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).

    Article  CAS  Google Scholar 

  4. Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).

    Article  CAS  Google Scholar 

  5. Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).

    Article  CAS  Google Scholar 

  6. Reichert, J.M. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995–1999. Trends Biotechnol. 18, 364–369 (2000).

    Article  CAS  Google Scholar 

  7. DiMasi, J. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297–307 (2001).

    Article  CAS  Google Scholar 

  8. Fox, S. Biopharmaceutical contract manufacturing: meeting increased demand for capacity. (HighTech Business Decisions, Moraga, CA; 2001).

Download references

Author information

Authors and Affiliations

  1. senior research fellow at the Tufts Center for the Study of Drug Development, Tufts, Boston, MA

    Janice M. Reichert

Authors
  1. Janice M. Reichert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reichert, J. Monoclonal antibodies in the clinic. Nat Biotechnol 19, 819–822 (2001). https://doi.org/10.1038/nbt0901-819

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0901-819

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing